| |
RA
|
Control
|
T test
|
P
|
|---|
|
Age (years) mean ± SD
|
45.5 ± 9.8
|
43.4 ± 7.7
|
0.7
|
0.5
|
|
Sex (male) n (%)
|
8 (36)
|
9 (40.9)
|
2.2
|
0.6
|
|
Age of onset (years) (mean ± SD)
|
25.5 ± 4.6
|
NA
|
NA
|
NA
|
|
Duration (years) (mean ± SD)
|
8.2±2.7
|
NA
|
NA
|
NA
|
|
Chest expansion (mean ± SD)
|
2 ± 1.6
|
3 ± 0.6
|
0.7
|
0.8
|
|
Seropositive RF
|
15 (68.2%)
|
0 (0%)
|
3
|
0.007*
|
|
Anti-ccp2
|
17(68.2%)
|
0(0%)
|
2.2
|
0.02*
|
|
DAS28-ESR (mean ± SD)
|
4.9 ± 0.7
|
NA
|
NA
|
NA
|
|
mHAQ (mean ± SD)
|
5 ± 1.09
|
NA
|
NA
|
NA
|
|
Medications n(%
|
|
Biological DMARDs
|
11 (50)
|
NA
|
NA
|
NA
|
|
Conventional DMARDs
|
5 (22.7)
| | | |
- RA rheumatoid arthritis, SD standard deviation, n number
- RF rheumatoid factor, Anti-ccp2 anti-cyclic citrullinated peptide, mHAQ modified health assessment questionnaire, DAS disease activity score, ESR erythrocyte sedimentation rate, DMARDs disease modifying agents for rheumatic diseases, NSAIDs non-steroidal anti-inflammatory drugs, NA not applicable
